Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.

Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF.

Med Care. 2002 Aug;40(8 Suppl):IV-3-18.

PMID:
12187163
2.

Treatment disparities for disabled medicare beneficiaries with stage I non-small cell lung cancer.

Iezzoni LI, Ngo LH, Li D, Roetzheim RG, Drews RE, McCarthy EP.

Arch Phys Med Rehabil. 2008 Apr;89(4):595-601. doi: 10.1016/j.apmr.2007.09.042. Review.

PMID:
18373987
3.

Administrative and claims records as sources of health care cost data.

Riley GF.

Med Care. 2009 Jul;47(7 Suppl 1):S51-5. doi: 10.1097/MLR.0b013e31819c95aa. Review.

PMID:
19536019
4.

Cancer burden in the aged: an epidemiologic and demographic overview.

Yancik R.

Cancer. 1997 Oct 1;80(7):1273-83. Review.

PMID:
9317180
5.

Linking Medicare and national survey data.

Lillard LA, Farmer MM.

Ann Intern Med. 1997 Oct 15;127(8 Pt 2):691-5. Review.

PMID:
9382381
6.

Record linkage for pharmacoepidemiological studies in cancer patients.

Herk-Sukel MP, Lemmens VE, Poll-Franse LV, Herings RM, Coebergh JW.

Pharmacoepidemiol Drug Saf. 2012 Jan;21(1):94-103. doi: 10.1002/pds.2205. Epub 2011 Aug 2. Review.

PMID:
21812067
7.

The surveillance, epidemiology, and end results program: a national resource.

Hankey BF, Ries LA, Edwards BK.

Cancer Epidemiol Biomarkers Prev. 1999 Dec;8(12):1117-21. Review. No abstract available.

8.

Surveillance Epidemiology and End Results (SEER) program and population-based research in urologic oncology: an overview.

Scosyrev E, Messing J, Noyes K, Veazie P, Messing E.

Urol Oncol. 2012 Mar-Apr;30(2):126-32. doi: 10.1016/j.urolonc.2009.11.005. Epub 2010 Apr 3. Review.

PMID:
20363162
9.

Lessons learnt about early prostate cancer from large scale databases: population-based pearls of wisdom.

Penson DF, Albertsen PC.

Surg Oncol. 2002 Jun;11(1-2):3-11. Review.

PMID:
12031863
10.

The changing face of cancer survivorship.

Rowland JH, Aziz N, Tesauro G, Feuer EJ.

Semin Oncol Nurs. 2001 Nov;17(4):236-40. Review.

PMID:
11764706
11.

The Surveillance, Epidemiology, and End Results (SEER) Program and Pathology: Toward Strengthening the Critical Relationship.

Duggan MA, Anderson WF, Altekruse S, Penberthy L, Sherman ME.

Am J Surg Pathol. 2016 Dec;40(12):e94-e102. Review.

12.

Using the Surveillance, Epidemiology, and End Results database to investigate rare cancers, second malignancies, and trends in epidemiology, treatment, and outcomes.

Lloyd S, Park HS, Decker RH, Wilson LD, Yu JB.

Curr Probl Cancer. 2012 Jul-Aug;36(4):191-9. doi: 10.1016/j.currproblcancer.2012.03.008. Epub 2012 Apr 10. Review. No abstract available.

PMID:
22495057
13.

SEER cancer registry biospecimen research: yesterday and tomorrow.

Altekruse SF, Rosenfeld GE, Carrick DM, Pressman EJ, Schully SD, Mechanic LE, Cronin KA, Hernandez BY, Lynch CF, Cozen W, Khoury MJ, Penberthy LT.

Cancer Epidemiol Biomarkers Prev. 2014 Dec;23(12):2681-7. doi: 10.1158/1055-9965.EPI-14-0490. Review.

14.

NCI SEER public-use data: applications and limitations in oncology research.

Yu JB, Gross CP, Wilson LD, Smith BD.

Oncology (Williston Park). 2009 Mar;23(3):288-95. Review. No abstract available.

15.

Cancer research in Mexico. An overview.

Benítez-Bribiesca L, Villa-Treviño S.

Arch Med Res. 1995;26 Spec No:S153-6. Review. No abstract available.

PMID:
8845641

Supplemental Content

Support Center